SQI Diagnostics said this week that Integrated Sciences will serve as the exclusive distributor for its in vitro diagnostic products in Australia.
Toronto-based SQI sells tests for rheumatoid arthritis and celiac disease. The assays are run on its SQiDWorks microarray platform. Both have been cleared for clinical use in Canada, the European Union, and the US.
SQI said that it will not need to submit the tests to Australian authorities to serve the local clinical market. A 2007 agreement between the Australian Therapeutic Goods Administration and the Department of Health of Canada permits diagnostic manufacturers from each country to export products to the other.
Sydney-based Integrated Sciences also acts as a distributor for a number of other molecular diagnostics and life science tools firms, including Autogenomics, Agilent Technologies, and NuGen Technologies.
Integrated Sciences director Michael Gaynor in a statement welcomed the deal, saying that the Australian firm has seen "many requests" from customers seeking automated multiplexed technologies to "replace existing manual and semi-automated diagnostic test systems."
Likewise, SQI CEO Claude Ricks said in a statement that Integrated Sciences has the "right combination of high-quality product offerings, experience, and customer exposure with high volume reference labs."
Integrated Sciences is SQI's first overseas distributor. SQI said that it continues to seek partners in geographies outside of Canada for its IVD products, as well as its diagnostic tools and services business. The company last year attempted to acquire Berlin-based Scienion, which would have given it direct access to the European market, but the deal was later abandoned (BAN 10/11/2011).